Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 1.00 |
| ▸ | PDE1A | P54750 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9101214 | 1.00 | MET (1.00) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL10162658 | 1.00 | MET (1.00) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL9101223 | 1.00 | MET (1.00) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL10162661 | 1.00 | MET (1.00) | METPDE1APDE4CPDE4DPDE3B | |
| SCHEMBL9103720 | 0.86 | MET (1.00) | MET | |
| SCHEMBL9103732 | 0.86 | MET (1.00) | MET | |
| SCHEMBL10162563 | 0.86 | MET (1.00) | MET | |
| SCHEMBL9103739 | 0.86 | MET (1.00) | MET | |
| SCHEMBL10162564 | 0.86 | MET (1.00) | MET | |
| SCHEMBL1163925 | 0.85 | MET (0.74) | METPDE1APDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | MET, HGF, RET | MET 1/4885PDE1A 3037/4885PDE4C 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.